Why Is CARIS LIFE SCIENCES (CAI) Stock Up Today?

Caris Life Sciences (CAI) surged 21.58% to $20.00 on Monday, driven by a strong second-quarter performance and an upward revision of its 2026 revenue guidance. The company reported a 45% year-over-year revenue increase to $263.7 million, driven by robust case volume and new product launches, including the Caris Detect platform. The stock’s sharp rise followed the release of its Q2 2026 earnings and the filing of an 8-K with the SEC disclosing the results.

What Happened

Caris Life Sciences delivered a standout second quarter, with revenue growth of 45.4% year-over-year and a first-time positive adjusted EBITDA. The company attributed the performance to strong demand in molecular profiling services, which included over 114,000 whole exome and whole transcriptome tests. Management raised full-year revenue guidance from $1.000B to $1.020B to $1.030B to $1.040B, exceeding the current estimate of $1.003B. The company also highlighted progress in scaling the Caris Detect platform toward a $3 billion annualized revenue run rate. These developments were announced in a press release and detailed during the Q2 2026 earnings call on August 5, 2026.

What The Data Shows

The stock has risen 25.1% over the past eight sessions, moving from $15.59 to $19.50 before today’s sharp increase. Insiders have been active buyers, with two directors purchasing shares totaling $1.5 million in the last 90 days, most recently on July 13. The company trades at a market cap of $4.6 billion, with a trailing 12-month revenue increase of 100.5% and a net margin of 3.7%. Despite a positive revenue trajectory, the company remains unprofitable with a trailing 12-month EPS of -1.80.

What To Watch

Caris Life Sciences has not scheduled an earnings report in the immediate future. Investors should monitor coverage breadth and any further guidance updates as the company scales its Detect platform and advances its MRD plans.